Cochlear Limited (CH:OC5)
:OC5
OC5 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Financial GuidanceFY26 guidance implies 2H26 NPAT growth of +13-25%.
Market GrowthThe Nucleus Nexa is the first 'smart' implant to market, expected to attract both physicians and patients and see double-digit growth for implants.
Product LaunchWith the launch of a new implant – the Nucleus Nexa – offering an enhanced patient experience, there is optimism that the company can sustain its market-leading position.
Bears Say
Market SentimentUncertainty around near-term services growth has led to a downgrade of COH shares from Buy to Neutral.
Product VolumeProcessors experienced a decline in volumes due to a mix of cost of living and other factors, making the outlook for services sales less optimistic.
Sales EstimatesMid-term sales estimates fall 5-6% on lower services sales growth, which resulted in a decrease in the price target from AUD350 to AUD320.
Cochlear News
OC5 FAQ
What was Cochlear Limited’s price range in the past 12 months?
Currently, no data Available
What is Cochlear Limited’s market cap?
Cochlear Limited’s market cap is CHF3.57B.
When is Cochlear Limited’s upcoming earnings report date?
Cochlear Limited’s upcoming earnings report date is Aug 13, 2026 which is in 70 days.
How were Cochlear Limited’s earnings last quarter?
Cochlear Limited released its earnings results on Feb 12, 2026. The company reported CHF1.671 earnings per share for the quarter, missing the consensus estimate of CHF1.766 by -CHF0.096.
Is Cochlear Limited overvalued?
According to Wall Street analysts Cochlear Limited’s price is currently Undervalued.
Does Cochlear Limited pay dividends?
Cochlear Limited does not currently pay dividends.
What is Cochlear Limited’s EPS estimate?
Cochlear Limited’s EPS estimate is 0.97.
How many shares outstanding does Cochlear Limited have?
Currently, no data Available
What happened to Cochlear Limited’s price movement after its last earnings report?
Cochlear Limited reported an EPS of CHF1.671 in its last earnings report, missing expectations of CHF1.766. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Cochlear Limited?
Currently, no hedge funds are holding shares in CH:OC5
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cochlear Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF75.39 (― Downside)
CHF75.39 (― Downside)
Blogger Sentiment
Bullish
CH:OC5 Sentiment 79%
Sector Average ―
Sector Average ―
News Sentiment
Bearish
Bullish news 33%
Bearish news 67%
Bearish news 67%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.82%
12-Months-Change
Fundamentals
Return on Equity
17.76%
Trailing 12-Months
Asset Growth
8.00%
Trailing 12-Months
Company Description
Cochlear Limited
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. The company was founded in 1981 and is headquartered in Sydney, Australia.
OC5 Company Deck
OC5 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a mixed picture: strategically positive with a largely successful Nexa launch, clear adoption in developed markets, services momentum and significant long‑term investments (cloud, R&D, capacity). However, near‑term financials were weaker than expected — H1 revenue down 2% cc, margin compression to 73%, A$103M cash decline and an A$30M potential FX hit for H2 — and the company experienced short‑term market share pressure during contracting and some softness in Acoustics. Management expects a stronger second half but guided to the lower end of prior FY guidance and emphasized that FX and timing delays constrained H1 results.View all CH:OC5 earnings summariesOC5 Stock 12 Month Forecast
Average Price Target
CHF75.39
Nova Eye Medical
―
Compumedics Limited
―
Somnomed Limited
―
Control Bionics Ltd.
―
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
―
Options Prices
Currently, No data available
---